Galectina-3 como biomarcador de riesgo de daño renal agudo en pacientes con insuficiencia cardiaca descompensada / Galectina-3 as a biomarker of acute kidney injury risk in patients with decompensated heart failure

Introducción: En descompensaciones por insuficiencia cardiaca (IC), tanto el daño renal agudo (DRA) como los niveles elevados de galectina-3 (Gal-3) se han asociado con una peor evolución. Los niveles plasmáticos de Gal-3 se ven influidos por la función renal; sin embargo, el posible papel de la Gal-3 como predictor de DRA no está establecido. Métodos: Se midieron las concentraciones de Gal-3 al ingreso en 175 pacientes hospitalizados por IC y se registró la aparición de DRA según los criterios analíticos RIFLE. Resultados: Durante el ingreso, 44 pacientes (25,1%) desarrollaron DRA, aunque solo 14 (8%) correspondían a los estadios más avanzados, siendo en estos los niveles de Gal-3 al ingreso significativamente mayores, permaneciendo como predictor de DRA tras el ajuste multivariado por otras variables predictoras y por función renal basal. Conclusiones: Los valores elevados de Gal-3 al ingreso se asocian a mayor riesgo de DRA durante la hospitalización por IC descompensada

Introduction: In decompensated heart failure (HF), both acute kidney injury (AKI) and high Galectina-3 (Gal-3) levels have been associated with poorer outcomes. Plasma Gal-3 levels are affected by renal function; however, the potential role of Gal-3 as a predictor of AKI has not been established. Methods: We measured Gal-3 concentrations at admission for 175 patients hospitalised for HF and recorded the onset of AKI according to the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) analytical criteria. Results: During hospitalisation, 44 patients (25.1%) developed AKI, although only 14 (8%) corresponded to more advanced stages. These 14 patients had significantly higher Gal-3 levels at admission, which remained a predictor of AKI after the multivariate adjustment by other predictors and by baseline renal function. Conclusions: High Gal-3 levels at admission are associated with a higher risk of AKI during hospitalisation for decompensated HF

Galectina-3 as a biomarker of acute kidney injury risk in patients with decompensated heart failure. / Galectina-3 como biomarcador de riesgo de daño renal agudo en pacientes con insuficiencia cardiaca descompensada.

INTRODUCTION: In decompensated heart failure (HF), both acute kidney injury (AKI) and high Galectina-3 (Gal-3) levels have been associated with poorer outcomes. Plasma Gal-3 levels are affected by renal function; however, the potential role of Gal-3 as a predictor of AKI has not been established. METHODS: We measured Gal-3 concentrations at admission for 175 patients hospitalised for HF and recorded the onset of AKI according to the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) analytical criteria. RESULTS: During hospitalisation, 44 patients (25.1%) developed AKI, although only 14 (8%) corresponded to more advanced stages. These 14 patients had significantly higher Gal-3 levels at admission, which remained a predictor of AKI after the multivariate adjustment by other predictors and by baseline renal function. CONCLUSIONS: High Gal-3 levels at admission are associated with a higher risk of AKI during hospitalisation for decompensated HF.